112 related articles for article (PubMed ID: 8032956)
1. 5-Fluorouracil pharmacokinetics in patients with metastatic colorectal carcinoma after high-dose leucovorin.
Stein TA; Burns GP; Bailey B; Citron ML
Cancer Invest; 1994; 12(4):375-8. PubMed ID: 8032956
[TBL] [Abstract][Full Text] [Related]
2. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group.
Petrelli N; Douglass HO; Herrera L; Russell D; Stablein DM; Bruckner HW; Mayer RJ; Schinella R; Green MD; Muggia FM
J Clin Oncol; 1989 Oct; 7(10):1419-26. PubMed ID: 2674331
[TBL] [Abstract][Full Text] [Related]
3. Plasma and salivary pharmacokinetics of 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer receiving 5-FU bolus plus continuous infusion with high-dose folinic acid.
Joulia JM; Pinguet F; Ychou M; Duffour J; Astre C; Bressolle F
Eur J Cancer; 1999 Feb; 35(2):296-301. PubMed ID: 10448274
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer.
Schilsky RL; Hohneker J; Ratain MJ; Janisch L; Smetzer L; Lucas VS; Khor SP; Diasio R; Von Hoff DD; Burris HA
J Clin Oncol; 1998 Apr; 16(4):1450-7. PubMed ID: 9552051
[TBL] [Abstract][Full Text] [Related]
5. Phase I clinical and pharmacokinetic study of leucovorin and infusional hepatic arterial fluorouracil.
Kerr DJ; Ledermann JA; McArdle CS; Buckels J; Neoptolemos J; Seymour M; Doughty J; Budden J; Taylor I
J Clin Oncol; 1995 Dec; 13(12):2968-72. PubMed ID: 8523062
[TBL] [Abstract][Full Text] [Related]
6. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer.
Borner MM; Schoffski P; de Wit R; Caponigro F; Comella G; Sulkes A; Greim G; Peters GJ; van der Born K; Wanders J; de Boer RF; Martin C; Fumoleau P
Eur J Cancer; 2002 Feb; 38(3):349-58. PubMed ID: 11818199
[TBL] [Abstract][Full Text] [Related]
7. Phase I, pharmacokinetic, and bone marrow drug-level studies of tri-monthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers.
Ho YF; Lu WC; Chen RR; Cheng AL; Yeh KH
Anticancer Drugs; 2011 Mar; 22(3):290-8. PubMed ID: 21150775
[TBL] [Abstract][Full Text] [Related]
8. Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients.
Falcone A; Danesi R; Dargenio F; Pfanner E; Brunetti I; Del Tacca M; Nethersell AB; Conte PF
J Clin Oncol; 1996 Mar; 14(3):729-36. PubMed ID: 8622018
[TBL] [Abstract][Full Text] [Related]
9. Dose and time dependencies of 5-fluorouracil pharmacokinetics.
Terret C; Erdociain E; Guimbaud R; Boisdron-Celle M; McLeod HL; Féty-Deporte R; Lafont T; Gamelin E; Bugat R; Canal P; Chatelut E
Clin Pharmacol Ther; 2000 Sep; 68(3):270-9. PubMed ID: 11014408
[TBL] [Abstract][Full Text] [Related]
10. Comparison of 5-fluorouracil pharmacokinetics in whole blood, plasma, and red blood cells in patients with colorectal cancer.
Wattanatorn W; McLeod HL; Macklon F; Reid M; Kendle KE; Cassidy J
Pharmacotherapy; 1997; 17(5):881-6. PubMed ID: 9324177
[TBL] [Abstract][Full Text] [Related]
11. Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa.
Harte RJ; Matthews JC; O'Reilly SM; Tilsley DW; Osman S; Brown G; Luthra SJ; Brady F; Jones T; Price PM
J Clin Oncol; 1999 May; 17(5):1580-8. PubMed ID: 10334547
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacokinetics of oxaliplatin and 5-fluorouracil administered in combination with leucovorin in Korean patients with advanced colorectal cancer.
Cho HK; Lee ES; Lee JW; Park JK; Kang JH; Lee KS; Shim CK; Chung SJ; Kim DD; Kuh HJ
J Cancer Res Clin Oncol; 2006 May; 132(5):320-6. PubMed ID: 16395593
[TBL] [Abstract][Full Text] [Related]
13. Influence of the administration of amifostine on the pharmacokinetics of 5-fluorouracil in patients with metastatic colorectal carcinoma.
Martens-Lobenhoffer J; Fuhlroth J; Ridwelski K
Int J Clin Pharmacol Ther; 2000 Jan; 38(1):41-4. PubMed ID: 10667836
[TBL] [Abstract][Full Text] [Related]
14. A dose-intensive regimen of 5-fluorouracil for the treatment of metastatic colorectal carcinoma.
Poplin EA; Kraut M; Baker L; Brodfuehrer J; Vaitkevicius V
Cancer; 1991 Jan; 67(2):367-71. PubMed ID: 1985732
[TBL] [Abstract][Full Text] [Related]
15. Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer.
Bressolle F; Joulia JM; Pinguet F; Ychou M; Astre C; Duffour J; Gomeni R
Cancer Chemother Pharmacol; 1999; 44(4):295-302. PubMed ID: 10447576
[TBL] [Abstract][Full Text] [Related]
16. Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients.
Gamelin E; Boisdron-Celle M; Delva R; Regimbeau C; Cailleux PE; Alleaume C; Maillet ML; Goudier MJ; Sire M; Person-Joly MC; Maigre M; Maillart P; Fety R; Burtin P; Lortholary A; Dumesnil Y; Picon L; Geslin J; Gesta P; Danquechin-Dorval E; Larra F; Robert J
J Clin Oncol; 1998 Apr; 16(4):1470-8. PubMed ID: 9552054
[TBL] [Abstract][Full Text] [Related]
17. Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma.
Peters GJ; Lankelma J; Kok RM; Noordhuis P; van Groeningen CJ; van der Wilt CL; Meyer S; Pinedo HM
Cancer Chemother Pharmacol; 1993; 31(4):269-76. PubMed ID: 8422689
[TBL] [Abstract][Full Text] [Related]
18. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma.
Poon MA; O'Connell MJ; Moertel CG; Wieand HS; Cullinan SA; Everson LK; Krook JE; Mailliard JA; Laurie JA; Tschetter LK
J Clin Oncol; 1989 Oct; 7(10):1407-18. PubMed ID: 2476530
[TBL] [Abstract][Full Text] [Related]
19. 5-FU split dose; a phase I/II and pharmacokinetic study of a different schedule of the Nordic regimen in advanced colorectal carcinoma.
Berglund A; Carlsson G; Gustavsson B; Frödin JE; Ragnhammar P; Glimelius B
Anticancer Res; 2003; 23(2C):1789-94. PubMed ID: 12820460
[TBL] [Abstract][Full Text] [Related]
20. Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: a randomized trial of the Northern California Oncology Group.
Valone FH; Friedman MA; Wittlinger PS; Drakes T; Eisenberg PD; Malec M; Hannigan JF; Brown BW
J Clin Oncol; 1989 Oct; 7(10):1427-36. PubMed ID: 2789272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
